KR102539877B1 - Gpr120 조정제로서 유용한 이환형 화합물 - Google Patents
Gpr120 조정제로서 유용한 이환형 화합물 Download PDFInfo
- Publication number
- KR102539877B1 KR102539877B1 KR1020197010276A KR20197010276A KR102539877B1 KR 102539877 B1 KR102539877 B1 KR 102539877B1 KR 1020197010276 A KR1020197010276 A KR 1020197010276A KR 20197010276 A KR20197010276 A KR 20197010276A KR 102539877 B1 KR102539877 B1 KR 102539877B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- membered
- group
- delete delete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393619P | 2016-09-12 | 2016-09-12 | |
| US62/393,619 | 2016-09-12 | ||
| PCT/US2017/050964 WO2018049328A1 (en) | 2016-09-12 | 2017-09-11 | Bicyclic compounds useful as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190068535A KR20190068535A (ko) | 2019-06-18 |
| KR102539877B1 true KR102539877B1 (ko) | 2023-06-05 |
Family
ID=61562078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197010276A Active KR102539877B1 (ko) | 2016-09-12 | 2017-09-11 | Gpr120 조정제로서 유용한 이환형 화합물 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10865201B2 (enExample) |
| EP (1) | EP3509588B1 (enExample) |
| JP (1) | JP7065081B2 (enExample) |
| KR (1) | KR102539877B1 (enExample) |
| CN (1) | CN110121343B (enExample) |
| WO (1) | WO2018049328A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102537985B1 (ko) | 2016-09-12 | 2023-05-30 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 단환형 화합물 |
| KR102539877B1 (ko) * | 2016-09-12 | 2023-06-05 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 이환형 화합물 |
| EP3781146A4 (en) * | 2018-04-20 | 2022-01-26 | Krish Biotech Research Private Limited | Method of treatment of non-alcoholic steatohepatitis, nash |
| CN111499592B (zh) * | 2020-03-14 | 2023-06-23 | 江苏省农用激素工程技术研究中心有限公司 | 5-氨甲基糖精的合成方法 |
| CN111574414A (zh) * | 2020-05-20 | 2020-08-25 | 上海毕得医药科技有限公司 | 一种4-溴-2-甲氧基苯磺酰氯的合成方法 |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| CN114685395A (zh) * | 2020-12-29 | 2022-07-01 | 浙江大学 | 一种2,3-二氢苯并[d]异噻唑类化合物及其应用 |
| CN117143039A (zh) * | 2022-08-29 | 2023-12-01 | 山东大学 | 一种苯并五元氮环类化合物、其制备方法及医药用途 |
| CN116730945B (zh) * | 2023-08-10 | 2023-11-17 | 北京惠宇乐邦环保科技有限公司 | 糖精的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010104195A1 (en) * | 2009-03-11 | 2010-09-16 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindolin-1-one derivative |
| WO2014096941A1 (en) * | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2735225A (en) | 1956-02-21 | Table ix p petri dish tests with x-phthalimido- | ||
| DE2253251A1 (de) * | 1972-10-30 | 1974-05-09 | Thomae Gmbh Dr K | Neue phthalimido-sulfonylharnstoffe |
| DE3474547D1 (en) * | 1983-12-02 | 1988-11-17 | Shell Int Research | Diphenyl ether herbicides |
| FR2659327A1 (fr) | 1990-03-08 | 1991-09-13 | Centre Nat Rech Scient | Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases. |
| DE69224115T2 (de) * | 1991-07-30 | 1998-08-20 | Ciba Geigy Ag | Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren |
| US5350761A (en) * | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| US5334600A (en) * | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
| TW219935B (enExample) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| US5599811A (en) * | 1995-02-21 | 1997-02-04 | Warner-Lambert Company | Benzothiazine dioxides as endothelin antagonists |
| EP0891332B1 (en) | 1996-03-29 | 2004-03-17 | Pfizer Inc. | 6-phenylpyridyl-2-amine derivatives |
| US6716836B2 (en) | 2001-03-22 | 2004-04-06 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| WO2008077550A1 (en) * | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| CN101646660A (zh) | 2007-02-22 | 2010-02-10 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
| KR101511396B1 (ko) | 2007-07-20 | 2015-04-13 | 추가이 세이야쿠 가부시키가이샤 | ｐ27 단백질 유도제 |
| JP2012506386A (ja) | 2008-10-21 | 2012-03-15 | メタボレックス， インコーポレイテッド | アリールｇｐｒ１２０受容体アゴニストおよびその使用 |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US8314120B2 (en) * | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| DK2582674T3 (en) | 2010-06-16 | 2014-12-15 | Cymabay Therapeutics Inc | GPR120 receptor agonists and uses thereof. |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| TW201200505A (en) * | 2010-06-17 | 2012-01-01 | Metabolex Inc | GPR120 receptor agonists and uses thereof |
| WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
| MX350717B (es) | 2011-11-30 | 2017-09-14 | Hoffmann La Roche | Nuevos derivados biciclicos de dihidroisoquinolin-1-ona. |
| WO2014059232A2 (en) | 2012-10-11 | 2014-04-17 | Merck Sharp & Dohme Corp. | Substituted spiropiperidinyl compounds useful as gpr120 agonists |
| KR101942752B1 (ko) | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| CN104968657A (zh) * | 2012-12-03 | 2015-10-07 | 弗·哈夫曼-拉罗切有限公司 | 被取代的三唑和咪唑化合物 |
| ES2629501T3 (es) | 2013-03-14 | 2017-08-10 | Janssen Pharmaceutica, N.V. | Derivados de pirrol bicíclicos útiles como agonistas de GPR12O |
| PL3421458T3 (pl) | 2013-03-14 | 2021-04-19 | Janssen Pharmaceutica Nv | Benzo-skondensowane heterocykliczne pochodne przydatne jako agonisty gpr120 |
| SI3013796T1 (sl) | 2013-06-27 | 2020-07-31 | Lg Chem, Ltd. | Biaril derivati kot GPR120 agonisti |
| TW201623286A (zh) * | 2014-04-04 | 2016-07-01 | 賽諾菲公司 | 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物 |
| HRP20180641T1 (hr) | 2014-05-07 | 2018-06-01 | Bristol-Myers Squibb Company | Pirolidinski gpr40 modulatori za liječenje bolesti kao što je dijabetes |
| EA037275B1 (ru) | 2014-08-29 | 2021-03-03 | Сиэйчдиай Фаундэйшн, Инк. | Зонды для визуализации белка хантингтина |
| JP6486699B2 (ja) | 2015-01-29 | 2019-03-20 | 国立大学法人金沢大学 | 脱水縮合剤 |
| WO2017068412A1 (en) * | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| KR102539877B1 (ko) * | 2016-09-12 | 2023-06-05 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 이환형 화합물 |
| KR102537985B1 (ko) * | 2016-09-12 | 2023-05-30 | 인테그랄 헬스 인코퍼레이티드 | Gpr120 조정제로서 유용한 단환형 화합물 |
-
2017
- 2017-09-11 KR KR1020197010276A patent/KR102539877B1/ko active Active
- 2017-09-11 JP JP2019513944A patent/JP7065081B2/ja active Active
- 2017-09-11 US US16/331,928 patent/US10865201B2/en active Active
- 2017-09-11 CN CN201780068712.9A patent/CN110121343B/zh active Active
- 2017-09-11 EP EP17849722.8A patent/EP3509588B1/en active Active
- 2017-09-11 WO PCT/US2017/050964 patent/WO2018049328A1/en not_active Ceased
-
2020
- 2020-12-14 US US17/121,165 patent/US11919891B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010104195A1 (en) * | 2009-03-11 | 2010-09-16 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindolin-1-one derivative |
| WO2014096941A1 (en) * | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018049328A1 (en) | 2018-03-15 |
| US20190218208A1 (en) | 2019-07-18 |
| EP3509588A1 (en) | 2019-07-17 |
| JP7065081B2 (ja) | 2022-05-11 |
| US11919891B2 (en) | 2024-03-05 |
| EP3509588C0 (en) | 2023-06-07 |
| KR20190068535A (ko) | 2019-06-18 |
| EP3509588A4 (en) | 2020-04-29 |
| JP2019533642A (ja) | 2019-11-21 |
| CN110121343B (zh) | 2023-11-03 |
| CA3041038A1 (en) | 2018-03-15 |
| US20210347768A1 (en) | 2021-11-11 |
| US10865201B2 (en) | 2020-12-15 |
| CN110121343A (zh) | 2019-08-13 |
| EP3509588B1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102539877B1 (ko) | Gpr120 조정제로서 유용한 이환형 화합물 | |
| KR102537985B1 (ko) | Gpr120 조정제로서 유용한 단환형 화합물 | |
| JP6838796B2 (ja) | メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物 | |
| TWI444378B (zh) | 具有β－分泌酶抑制作用之含硫雜環衍生物及其用途 | |
| KR102240158B1 (ko) | 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 | |
| US8940769B2 (en) | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | |
| US20070149547A1 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| JP2009533410A (ja) | Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体 | |
| US20120172333A1 (en) | Pyrrolo-pyridine derivatives as activators of ampk | |
| JP2020515631A (ja) | 縮合二環式化合物、その組成物及び応用 | |
| EP1003724B1 (de) | Substituierte-chinolin-derivate mit antiviraler wirkung | |
| KR20120101551A (ko) | Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸 | |
| CA3041038C (en) | Bicyclic compounds useful as gpr120 modulators | |
| KR20160068948A (ko) | RORyt의 이차 알코올 퀴놀리닐 조절제 | |
| HK40005335B (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005335A (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005332A (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005332B (en) | Monocyclic compounds useful as gpr120 modulators | |
| CA2927152C (en) | Phenyl linked quinolinyl modulators of ror-gamma-t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |